A therapeutic milestone

On 14 September 1990, four-year-old Ashanthi DeSilva received genetically modified immune cells in a pioneering trial for adenosine deaminase deficiency at the National Institutes of Health. A second child, Cindy Cutshall, entered treatment in January 1991. The programme involved R. Michael Blaese, W. French Anderson, Kenneth Culver and a wider clinical and laboratory team.

The description “first human gene therapy trial” requires qualification. An approved NIH experiment in 1989 had already introduced a marker gene into human lymphocytes to track the cells. The ADA trial took the additional step of introducing a gene intended to compensate for an inherited disease. Its historical importance lies in this therapeutic purpose, rather than in being the first occasion on which any foreign gene entered a human cell. The National Library of Medicine’s archival account documents that transition and the extensive preparations behind it.

Why ADA deficiency?

ADA deficiency can cause severe combined immunodeficiency, or ADA-SCID. Defective enzyme activity allows harmful metabolic products to accumulate, damaging immune cells and leaving affected children vulnerable to repeated infections. The disease connected an identifiable genetic defect with a measurable enzyme deficiency, making it a compelling target for experimental gene transfer.

Existing approaches included bone marrow transplantation and enzyme replacement with polyethylene glycol-conjugated ADA, known as PEG-ADA. The trial therefore entered an established therapeutic landscape. Its participants continued enzyme replacement while receiving modified cells. This protected them, but complicated interpretation: improvements could not automatically be attributed entirely to gene transfer.

The NIH’s 1995 account explicitly acknowledged this uncertainty. Blaese explained that withdrawing enzyme treatment might clarify the experiment scientifically while exposing the children to unacceptable uncertainty clinically. The episode illustrates a lasting tension in clinical research: obtaining clearer evidence must be weighed against the welfare of participants.

What the experiment established

Researchers used a retroviral vector to introduce a functioning ADA gene into T lymphocytes collected from the children. The modified cells were then returned to their bodies. This was gene addition in cells treated outside the body; it did not precisely repair the inherited mutation throughout the patient. Its immediate target was a population of immune cells.

In their 1995 report in Science, the investigators described normalization of blood T-cell numbers and improvement in several measures of cellular and antibody-mediated immunity. Introduced genetic material and ADA expression persisted after the course of cell treatment ended.

These findings supported the feasibility of sustained therapeutic gene expression in humans. They did not establish a universal cure for inherited disease. The authors framed gene therapy as a potentially useful addition to treatment for selected patients. That distinction matters historically: demonstrating that modified cells could survive and function was a substantial achievement, while establishing independent clinical benefit required further evidence.

Long-term evidence and legacy

A 2003 follow-up by Linda Mesler Muul and colleagues revealed striking differences between the two participants. Ten years after the final infusion, approximately 20 percent of the first patient’s lymphocytes still carried and expressed the transferred gene. In the second patient, gene-marked cells were below 0.1 percent and expression was undetectable; she had developed persistent antibodies against components of the gene-transfer system. Both continued PEG-ADA at reduced doses.

The investigators reported no observed adverse events, but results from two participants cannot establish the safety of every vector or subsequent treatment. The study nevertheless supplied unusually long observation of genetically modified human T cells and demonstrated that gene expression could persist for years.

Taken together, the early and later reports support a measured historical interpretation. The trial opened a practical route toward treating inherited disease through genetic modification, while exposing problems of consistency, immune response and attribution of benefit. Its legacy includes the importance of following patients long after a celebrated first procedure. This account describes an experimental historical protocol, not instructions for present-day care.

Sources